DSM Successfully Completes Tender Offer for Martek and Expects to Complete Acquisition Today
(Thomson Reuters ONE) -
Royal DSM N.V. (NYSE Euronext: DSM KON), the global Life Sciences and Materials
Sciences company, announced today that it has successfully completed the
subsequent offering period to its all-cash tender offer to purchase all of the
outstanding shares of common stock of Martek Biosciences Corporation at a price
of $31.50 per share.
The previously announced subsequent offering period expired at 12:00 midnight,
New York City time, on Thursday, February 24, 2011. The depositary for the
tender offer has advised that, as of such time, a total of approximately
262,000 additional Martek shares of common stock had been validly tendered in
the subsequent offering period, which, together with the shares validly tendered
and not withdrawn during the initial offering period, resulted in DSM holding
approximately 89.5% of Martek's currently outstanding shares. DSM has accepted
for payment all validly tendered shares.
DSM intends to exercise the top-up option that was granted to DSM pursuant to
the merger agreement to purchase additional shares directly from Martek and to
complete a short-form merger in accordance with the merger agreement later
today. In the short-form merger, Greenback Acquisition Corporation will be
merged with and into Martek, and each share of Martek common stock not tendered
in the tender offer, other than those as to which holders exercise appraisal
rights under Delaware law and those held by DSM or Martek or their respective
subsidiaries, will be converted in the merger into the right to receive $31.50
per share in cash, without interest and less any required withholding taxes.
This is the same price per share paid in the tender offer.
Martek
Martek is a leader in the innovation, development, production and sale of high-
value products from microbial sources that promote health and wellness through
nutrition. Martek's technology platform consists of its core expertise, broad
experience and proprietary technology in areas such as microbial biology, algal
genomics, fermentation and downstream processing. This technology platform has
resulted in Martek's development of a number of products, including the
company's flagship product, life'sDHA(TM), a sustainable and vegetarian source
of algal DHA (docosahexaenoic acid) important for brain, heart and eye health
throughout life for use in infant formula, pregnancy and nursing products, foods
and beverages, dietary supplements and animal feeds. Martek also
produces life'sARA(TM) (arachidonic acid), an omega-6 fatty acid, for use in
infant formula and follow-on formulas. Martek's subsidiary, Amerifit Brands,
develops, markets and distributes branded consumer health and wellness products
and holds leading brand positions in all of its key product categories. Amerifit
products are sold in most major mass, club, drug, grocery and specialty stores
and include: Culturelle®, a leading probiotic supplement; AZO, the leading OTC
brand addressing symptom relief and detection of urinary tract infections; and
Estroven®, the leading all-natural nutritional supplement brand addressing the
symptoms of menopause.
For more information on Martek Biosciences, visit www.martek.com. For a complete
list of life'sDHA(TM) and life'sARA(TM) products, visit www.lifesdha.com. For
more information about Amerifit Brands, visit http://www.amerifit.com.
DSM - Bright Science. Brighter Living.(TM)
Royal DSM N.V. is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders. DSM delivers
innovative solutions that nourish, protect and improve performance in global
markets such as food and dietary supplements, personal care, feed,
pharmaceuticals, medical devices, automotive, paints, electrical and
electronics, life protection, alternative energy and bio-based materials. DSM's
22,000 employees deliver annual net sales of about ? 9 billion. The company is
listed on NYSE Euronext. More information can be found at www.dsm.com
For more information:
DSM Corporate Communications DSM Investor Relations
Herman Betten Hans Vossen
tel. +31 (0) 45 5782017 tel. +31 (0) 45 5782864
fax +31 (0) 45 5740680 fax +31 (0) 10 4590275
e-mail media.relations(at)dsm.com e-mail investor.relations(at)dsm.com
Press release-pdf:
http://hugin.info/130663/R/1492376/428156.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DSM N.V. via Thomson Reuters ONE
[HUG#1492376]
Unternehmensinformation / Kurzprofil:
Datum: 25.02.2011 - 08:15 Uhr
Sprache: Deutsch
News-ID 51903
Anzahl Zeichen: 5754
contact information:
Town:
Heerlen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 202 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DSM Successfully Completes Tender Offer for Martek and Expects to Complete Acquisition Today"
steht unter der journalistisch-redaktionellen Verantwortung von
DSM N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
